Thymidine Kinase Type 1 and C-Reactive Protein Concentrations in Dogs with Spontaneously Occurring Cancer

K. A. Selting, R. Ringold, B. Husbands, P. O. Pithua

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BACKGROUND: Serum thymidine kinase type 1 (TK1) and canine C-Reactive Protein (cCRP) might be useful in detecting dogs with cancer. Algorithms combining biomarkers are sometimes more accurate than results of individual tests.

OBJECTIVES: The aim of this study was to compare serum TK1 and cCRP and Neoplasia Index (NI) in healthy and tumor-bearing dogs.

ANIMALS: Client-owned dogs with (n = 253) and without (n = 156) cancer.

METHODS: Retrospective case-control study. Dogs with cancer were identified after submission of samples for commercial assay and case details were retrospectively collected. Healthy dogs (control) were identified through breed groups and health status was confirmed by health questionnaire for a minimum of 6 months. Serum TK1 activity was measured using a quantitative chemiluminescent assay and serum cCRP was measured using a quantitative ELISA assay.

RESULTS: TK1 activity in the cancer (n = 253) and control group (n = 156) were 7.0 μ/L (median, range <0.5 to >100) and 1.8 μ/L (median, range 0.4 to 55.3), respectively (P < .001). cCRP concentrations in the cancer and control group were 6.0 mg/L (median, range <0.5 to >50) and 1.6 mg/L (median, range 0.09 to >50), respectively (P < .001). The NI in the cancer and control group were 6.4 (median, range 0-9.9) and 0.9 (median, range 0-7.6), respectively (P < .001). ROC AUCs of the NI and TK1 for all cancers were greater than 0.8, highest for lymphoma and histiocytic sarcoma.

CONCLUSIONS AND CLINICAL IMPORTANCE: Increased concentrations of TK1 and cCRP, when present in dogs with cancer, might be useful in confirming a diagnosis and monitoring response to treatment.

Original languageEnglish (US)
Pages (from-to)1159-1166
Number of pages8
JournalJournal of veterinary internal medicine
Volume30
Issue number4
DOIs
StatePublished - Jul 1 2016

Fingerprint

thymidine kinase
C-reactive protein
C-Reactive Protein
Dogs
neoplasms
dogs
Neoplasms
Canidae
Serum
assays
thymidine kinase 1
Histiocytic Sarcoma
Luminescent Measurements
Control Groups
sarcoma
case-control studies
lymphoma
health status
Health Status
Area Under Curve

Keywords

  • Biomarker
  • Inflammation
  • Monitoring
  • Screening

Cite this

Thymidine Kinase Type 1 and C-Reactive Protein Concentrations in Dogs with Spontaneously Occurring Cancer. / Selting, K. A.; Ringold, R.; Husbands, B.; Pithua, P. O.

In: Journal of veterinary internal medicine, Vol. 30, No. 4, 01.07.2016, p. 1159-1166.

Research output: Contribution to journalArticle

@article{1df26eea9508424ba49f0788ed2f8d02,
title = "Thymidine Kinase Type 1 and C-Reactive Protein Concentrations in Dogs with Spontaneously Occurring Cancer",
abstract = "BACKGROUND: Serum thymidine kinase type 1 (TK1) and canine C-Reactive Protein (cCRP) might be useful in detecting dogs with cancer. Algorithms combining biomarkers are sometimes more accurate than results of individual tests.OBJECTIVES: The aim of this study was to compare serum TK1 and cCRP and Neoplasia Index (NI) in healthy and tumor-bearing dogs.ANIMALS: Client-owned dogs with (n = 253) and without (n = 156) cancer.METHODS: Retrospective case-control study. Dogs with cancer were identified after submission of samples for commercial assay and case details were retrospectively collected. Healthy dogs (control) were identified through breed groups and health status was confirmed by health questionnaire for a minimum of 6 months. Serum TK1 activity was measured using a quantitative chemiluminescent assay and serum cCRP was measured using a quantitative ELISA assay.RESULTS: TK1 activity in the cancer (n = 253) and control group (n = 156) were 7.0 μ/L (median, range <0.5 to >100) and 1.8 μ/L (median, range 0.4 to 55.3), respectively (P < .001). cCRP concentrations in the cancer and control group were 6.0 mg/L (median, range <0.5 to >50) and 1.6 mg/L (median, range 0.09 to >50), respectively (P < .001). The NI in the cancer and control group were 6.4 (median, range 0-9.9) and 0.9 (median, range 0-7.6), respectively (P < .001). ROC AUCs of the NI and TK1 for all cancers were greater than 0.8, highest for lymphoma and histiocytic sarcoma.CONCLUSIONS AND CLINICAL IMPORTANCE: Increased concentrations of TK1 and cCRP, when present in dogs with cancer, might be useful in confirming a diagnosis and monitoring response to treatment.",
keywords = "Biomarker, Inflammation, Monitoring, Screening",
author = "Selting, {K. A.} and R. Ringold and B. Husbands and Pithua, {P. O.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1111/jvim.13954",
language = "English (US)",
volume = "30",
pages = "1159--1166",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Thymidine Kinase Type 1 and C-Reactive Protein Concentrations in Dogs with Spontaneously Occurring Cancer

AU - Selting, K. A.

AU - Ringold, R.

AU - Husbands, B.

AU - Pithua, P. O.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - BACKGROUND: Serum thymidine kinase type 1 (TK1) and canine C-Reactive Protein (cCRP) might be useful in detecting dogs with cancer. Algorithms combining biomarkers are sometimes more accurate than results of individual tests.OBJECTIVES: The aim of this study was to compare serum TK1 and cCRP and Neoplasia Index (NI) in healthy and tumor-bearing dogs.ANIMALS: Client-owned dogs with (n = 253) and without (n = 156) cancer.METHODS: Retrospective case-control study. Dogs with cancer were identified after submission of samples for commercial assay and case details were retrospectively collected. Healthy dogs (control) were identified through breed groups and health status was confirmed by health questionnaire for a minimum of 6 months. Serum TK1 activity was measured using a quantitative chemiluminescent assay and serum cCRP was measured using a quantitative ELISA assay.RESULTS: TK1 activity in the cancer (n = 253) and control group (n = 156) were 7.0 μ/L (median, range <0.5 to >100) and 1.8 μ/L (median, range 0.4 to 55.3), respectively (P < .001). cCRP concentrations in the cancer and control group were 6.0 mg/L (median, range <0.5 to >50) and 1.6 mg/L (median, range 0.09 to >50), respectively (P < .001). The NI in the cancer and control group were 6.4 (median, range 0-9.9) and 0.9 (median, range 0-7.6), respectively (P < .001). ROC AUCs of the NI and TK1 for all cancers were greater than 0.8, highest for lymphoma and histiocytic sarcoma.CONCLUSIONS AND CLINICAL IMPORTANCE: Increased concentrations of TK1 and cCRP, when present in dogs with cancer, might be useful in confirming a diagnosis and monitoring response to treatment.

AB - BACKGROUND: Serum thymidine kinase type 1 (TK1) and canine C-Reactive Protein (cCRP) might be useful in detecting dogs with cancer. Algorithms combining biomarkers are sometimes more accurate than results of individual tests.OBJECTIVES: The aim of this study was to compare serum TK1 and cCRP and Neoplasia Index (NI) in healthy and tumor-bearing dogs.ANIMALS: Client-owned dogs with (n = 253) and without (n = 156) cancer.METHODS: Retrospective case-control study. Dogs with cancer were identified after submission of samples for commercial assay and case details were retrospectively collected. Healthy dogs (control) were identified through breed groups and health status was confirmed by health questionnaire for a minimum of 6 months. Serum TK1 activity was measured using a quantitative chemiluminescent assay and serum cCRP was measured using a quantitative ELISA assay.RESULTS: TK1 activity in the cancer (n = 253) and control group (n = 156) were 7.0 μ/L (median, range <0.5 to >100) and 1.8 μ/L (median, range 0.4 to 55.3), respectively (P < .001). cCRP concentrations in the cancer and control group were 6.0 mg/L (median, range <0.5 to >50) and 1.6 mg/L (median, range 0.09 to >50), respectively (P < .001). The NI in the cancer and control group were 6.4 (median, range 0-9.9) and 0.9 (median, range 0-7.6), respectively (P < .001). ROC AUCs of the NI and TK1 for all cancers were greater than 0.8, highest for lymphoma and histiocytic sarcoma.CONCLUSIONS AND CLINICAL IMPORTANCE: Increased concentrations of TK1 and cCRP, when present in dogs with cancer, might be useful in confirming a diagnosis and monitoring response to treatment.

KW - Biomarker

KW - Inflammation

KW - Monitoring

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=84971212720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971212720&partnerID=8YFLogxK

U2 - 10.1111/jvim.13954

DO - 10.1111/jvim.13954

M3 - Article

VL - 30

SP - 1159

EP - 1166

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 4

ER -